FDA, Schizophrenia
Breakthrough in Schizophrenia Treatment: FDA Approves Cobenfy
New drug offers hope for patients with Schizophrenia that has long eluded effective treatment. Read on to know more.
FDA approves schizophrenia treatment
The FDA has approved Cobenfy capsules from Bristol-Myers Squibb for the oral treatment of schizophrenia in adults. The medication, formerly known as KarXT, is the first antipsychotic medication to ...
New schizophrenia drug gets FDA approval, taking novel approach to treating brain disorder
On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral medication that is manufactured by Bristol Myers Squibb in New Jersey.
In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
The U.S. Food and Drug Administration (FDA) approved a novel antipsychotic schizophrenia drug late Thursday, marking the first new treatment in decades for the mental health condition that affects 1.8 percent of the U.
FDA approves first new medication to treat schizophrenia in more than 30 years
People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental illness in more than 30 years.
FDA Approves First Novel Schizophrenia Drug in 70 Years, Impacting Up to 3 Million Patients in...
The FDA has approved Bristol Myers Squibb’s new schizophrenia drug, Cobenfy, the first novel treatment for schizophrenia in over 70 years. Schizophrenia affects nearly 3 million U.S. adults, but only 1.
FDA Approves the First New Type of Schizophrenia Drug in Decades
Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle movement, and sedation — that can cause patients to discontinue treatment.
Time2d
FDA Approves the First New Schizophrenia Drug in Decades
26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric disorder. Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb ...
ABC News3d
FDA approves 1st new drug for schizophrenia in more than 30 years
The medication, Cobenfy, combines two drugs and is taken as a twice-daily pill. The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with ...
Gizmodo3d
FDA Approves Potentially Groundbreaking Schizophrenia Drug
People living with schizophrenia will soon have a new and potentially groundbreaking treatment available. It’s called Cobenfy, and it’s the first new drug for the mental health condition to be ...
The Hill2d
FDA approves new type of schizophrenia drug
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
The Washington Post3d
FDA approves a novel drug for schizophrenia, a potential ‘game changer’
“This drug takes the first new approach to schizophrenia treatment in decades,” Tiffany Farchione, director of FDA’s division of psychiatry, said in a statement. “This approval offers a ...
Today5d
FDA issues recall notices over 2 brands of pet food due to salmonella and listeria risk
Amid an ongoing pet food recall, the U.S. Food and Drug Administration (FDA) is urging pet owners not to give their dogs and cats certain food products from two different brands. Both the brands ...
Coventry Telegraph3d
Man arrested for sending 'sexual messages' to 14-year-old child in Coventry
A man has been arrested on suspicion of sending sexual messages to a child in Coventry. He was detained in Walsgrave on Monday (September 23). Officers arrested the 39-year-old man, who has not ...
Medical Xpress3d
FDA approves new kind of drug for schizophrenia
It is a severe, chronic mental illness that is often damaging to a person's quality of life," said Dr. Tiffany Farchione, director of psychiatry in the Office of Neuroscience in the FDA's Center ...
Boise State Public Radio2d
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...